Annual number of outpatient visits in all eyes. by Yasuyuki Sotani (20114144)

“…<p>Mean visit frequency (mean ± standard deviation) significantly decreased from 11.5 ± 4.3 preoperatively to 8.8 ± 4.1, 5.0 ± 3.4, and 4.4 ± 3.2 visits in the first, second, and third postoperative years, respectively (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”

Annual number of outpatient visits in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

Time course of best-corrected visual acuity (BCVA) in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

Time course of central retinal thickness (CRT) in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

Time course of best-corrected visual acuity (BCVA) in all eyes. by Yasuyuki Sotani (20114144)

Annual treatment frequencies in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

“…<p>In the recurrence group, the respective treatment counts for anti-VEGF, STTA, MA-PC, PPV, and total treatments (mean ± standard deviation) in the year before surgery were 3.0 ± 1.4, 0.1 ± 0.3, 0.8 ± 1.0, 0.1 ± 0.3, and 4.0 ± 2.1, respectively. These significantly decreased to 2.3 ± 2.6, 0.1 ± 0.3, 0.8 ± 1.6, 0.0, and 3.1 ± 2.8 in the first year; 2.1 ± 2.8, 0.4 ± 1.0, 0, 0.1 ± 0.3, and 2.6 ± 2.8 in the second year; and 2.0 ± 2.2, 0, 0.6 ± 1.7, 0.1 ± 0.3, and 2.8 ± 3.5 in the third year (Kruskal–Wallis test, p < 0.001; Dunn’s test, *P < 0.05, **P < 0.01). …”

Annual treatment frequencies in all eyes. by Yasuyuki Sotani (20114144)

“…<p>The number of anti-VEGF treatments, STTA, MA-PC, PPV, and total treatments (mean ± SD) significantly decreased from 2.6 ± 1.6, 0.3 ± 0.8, 0.6 ± 0.8, 0.1 ± 0.3, and 3.7 ± 1.7 preoperatively to 0.8 ± 1.9, 0.0 ± 0.2, 0.3 ± 1.0, 0.0, and 1.2 ± 2.2; at year 2 to 0.7 ± 2.0, 0.1 ± 0.6, 0.0 ± 0.2, 0.0 ± 0.2, and 1.0 ± 2.1; and at year 3 to 0.9 ± 2.2, 0.0, 0.2 ± 1.0, 0.0 ± 0.2, and 1.1 ± 3.1 (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”

Time course of central retinal thickness (CRT) in all eyes. by Yasuyuki Sotani (20114144)

Median cost (USD) per visit breakdown. by Drew B. Cameron (10687420)

Hypothesis test for model specification and statistical assumptions. by James Anaba Akolgo (14129379)

Crude and adjusted times and hazard ratios for child mortality. by Samuel Sendagala (21417164)

Subjects:

Baseline characteristics of mother–infant pairs by child mortality status (N = 11,519). by Samuel Sendagala (21417164)

Subjects:

Child mortality rate per 1,000 person-years during the 18-month follow-up period. by Samuel Sendagala (21417164)

Subjects:

Kaplan–Meier cumulative survival curve for infants exposed and not exposed to HIV. by Samuel Sendagala (21417164)

Subjects:

Mortality dataset used in analysis. by Samuel Sendagala (21417164)

Subjects:

COVID19 effect on essential services. by Admas Abera (11821659)

“…The difference in the trends of services before and during COVID-19 was compared using linear-by-linear tests and the difference of magnitude across the indicators was compared using Autoregressive Integrated Moving Average (ARIMA) interrupted time series analysis at a 5% significance level.…”

Sociodemographic characteristics of participants at baseline, overall and by age group. by Chelsea S. Lutz (16001569)

Subjects:

Symptoms self-reported and/or documented in the electronic health record during the acute COVID-19 illness, by hospitalization status and age group. by Chelsea S. Lutz (16001569)

Subjects:

Sociodemographic and clinical characteristics associated with PCC at three months post-acute illness among adults enrolled during Omicron predominance. by Chelsea S. Lutz (16001569)

Subjects:

Manifestations of Post-COVID-19 Conditions (PCC) three months post-acute illness, among those with PCC, by age group^a. by Chelsea S. Lutz (16001569)

Subjects: